Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. MIMPARA
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
  • Date 23 April 2014
  • Documents : 2
  • History
Download opinion
Listen Listen
Add to my selection
  • Clinical Benefit
Quote this publication
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MIMPARA

-
Opinions on drugs - Posted on May 26 2014

Reason for request

Renewal of inclusion

-


Clinical Benefit

Substantial

Maintenance of the substantial actual benefit in the Marketing Authorisation indications.


Documents

  • MIMPARA_23042014_AVIS_CT9634 Xvox

English version

  • MIMPARA ENGLISH VERSION CT9634 Xvox
All our publications
    Drug therapy Endocrine gland cancers Endocrine system diseases Metabolic diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
eNq1mF1v2jAUhu/5FVEudkdC+Ch0S6g2RjekVmMUtGk3yCQHMAt26g9K++vnEFjp5KidwZeJk/cc+xw/fuXwartOnQ0wjimJ3MCruQ6QmCaYLCJ3Mr6udtyrbiVcoQ06+qzt1byg7jpxijiP3HzUmwEi3Pt5e/MZ1P/A3G7FCelsBbF48Z0UOPW+Ir68RVn+jRNuKE6cNYglTSI3k2L31gm5YCqL7gNlv3mGYgj9/Zvj0dW0efw+9HOxN6hKDuwGkYVWFIiRZiwZAyJ6SMCCsseSfBtG2piPgFPJYhgisRwyusEJJNoQc5RyMAoyf0jugG1SEHkQrbi/itfcSByt0HYE9wN90h/VaE9sRbVWDdqtenARtDrNy1bbKBQ7Wip9FdQk/HgatJuNxkXdB+Kv8TpDDBnWZkiZQKmlqmDee9lYluIwuH+1+gnmWYoevRXPTJdKrbIaBqa2v72J5DMYMwWkVK3ZP/pEpqn/n1lP9riwlHFOox6VRJRQ43pkuhA9SgRsyytqBjqx3fciBn4+2SdK9JAfylmKY1OkKehI4GIyGpQT7Zww+IQ4TJg9GvzAJKEP/PyUOa6qpeyzHSi1ohlLgmn9sqPI3zLeRL9UC5WcMH3JaAa+4g/mp2BlQOb0VKCortRLHXrybO248zk0RimUOJ2qIVtUHx6MmbVOt7eLigGt6Jf+2LQ9vktgj3e7R600TqK/hTUDrw2aq2Z8LfFi20bZtFFrdS4bzXdonX04WOjI0C4XolbcsmR6xiyFyPh7318iXuVIraU3Z+X8v9JO+xxTV7B9rqQ9M2/l8C/MUAFaS6nPihP07SU03bCvWYNT7e7+/72t1sYQTMIJdSjYbo3Ag/75of7sda2lPXyBFnthdr4UCUyJLb8kZ1rF044RVVdyzRQcvs3nuORipbQvQ7+41OlWQj+/0OlW/gDIQP0G
guZe3Z7cS6dw3WfQ